| Assessment Status |
Pre-submission consultation scheduled |
| HTA ID |
25026 |
| Drug |
Avapritinib |
| Brand |
Ayvakyt® |
| Indication |
Avapritinib is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. |
| Rapid review commissioned |
24/03/2025 |
| Rapid review completed |
17/04/2025 |
| Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of avapritinib compared with the current standard of care. |
| Full HTA commissioned by the HSE |
01/05/2025 |
